Stock Detail
Sector:
Latest Quote @ Fri May 5 05:59:27 (15 min delayed)
Last Day's Data
| $0.00 |
$0.00 |
$0.00 |
0.00% |
0.00 |
$0.00 |
| $0.00 |
$0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Stock Profile
BioMimetic Therapeutics, Inc. engages in the development and commercialization of bio-active drug-device combination products for healing musculoskeletal injuries and diseases that include periodontal, orthopedic, spine, and sports injury applications. It primarily engages in the development of the treatment for bone loss associated with advanced periodontal disease, and repair and regeneration of orthopedic tissues, including bone, cartilage, and ligaments or tendons. The company's GEM 21S Growth-factor Enhanced Matrix (GEM) is a synthetic regeneration system that combines a recombinant human platelet-derived growth factor with a synthetic bone matrix called beta-tricalcium phosphate in order to treat periodontal bone defects and gum tissue recession associated with periodontal diseases. It also develops GEM product candidates in the field of orthopedics, including bone, tendon, ligament, and cartilage applications. The company also develops GEM OS1 for the treatment of open fractures; GEM OS2 for the treatment of closed fractures; and other GEM OS product candidates for the areas of the skeletons, such as the vertebral bodies of the spine in osteoporotic individuals that are susceptible to fracture, and where stimulation of new bone formation could have a prophylactic therapeutic benefits. In addition, the company's pre-clinical development products include GEM C and GEM LT, which are used for various sports injuries, including those requiring cartilage, ligament, and tendon repair. Further, it offers GEM ONJ for treating osteonecrosis of the jaws. BioMimetic Therapeutics has a partnership with Luitpold Pharmaceuticals, Inc. for the marketing and distribution of GEM 21S worldwide. The company was founded in 1999. It was formerly known as BioMimetic Pharmaceuticals, Inc. and company changed its name to BioMimetic Therapeutics, Inc. in 2005. BioMimetic Therapeutics is headquartered in Franklin, Tennessee.
